Wood has been selected by leading biopharmaceutical firm, Celltrion, to expand its Songdo biopharma manufacturing hub in Incheon, South Korea.
Under this contract, Wood will provide detailed engineering design for a new facility that will increase manufacturing capacity of biological medicines by eight million liquid vials per year, helping meet global demand for biopharmaceutical drug products.
Supporting Celltrion to expand its product pipeline and secure manufacturing capacity, Wood’s leading process engineering design capabilities will help Celltrion enhance production efficiency and reduce downtime transitioning equipment from one product to another, resulting in facility operational cost savings.
Jim Goff, Senior Vice President of Life Sciences at Wood said: “Celltrion’s new facility will support secure, stable supply of life-changing medicines to help treat cancer, autoimmune diseases and neurological disorders. We’re incredibly proud to be selected as the engineering partner of choice for such a globally significant project.
“We take pride in our strong, predictable project delivery held at the highest safety and quality standards. Our differentiated process design expertise brings the agility needed to help Celltrion achieve new efficiencies in production, time and costs. We are supporting their commitment to expand global access to innovative biologics products for a healthier world.”
The project will be delivered by Wood’s global Life Sciences experts in Europe and India and will conclude in Q3 2024, with commercial operation set to begin in 2027.
Source: Wood Plc
Add a Comment